Trevena, Inc. (TRVN) Appoints Julie H. Mchugh And Barbara Yanni To The Board Of Directors
7/1/2014 11:59:17 AM
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Julie H. McHugh, former president of Centocor and chief operating officer at Endo Health Solutions, and Barbara Yanni, former chief licensing officer at Merck & Co., have joined Trevena’s Board of Directors. The two directors replace Terrance G. McGuire and David F. Solomon who are stepping down from the Board following the Company’s recent initial public offering.
Help employers find you! Check out all the jobs and post your resume.
comments powered by